10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Top Cited Papers
Open Access
- 17 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (12), 1685-1694
- https://doi.org/10.1093/cid/cit152
Abstract
Infections caused by antibiotic-resistant bacteria, especially the “ESKAPE” pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually approved for marketing in the United States continues to decline. We identified 7 drugs in clinical development for treatment of infections caused by resistant GNB. None of these agents was included in our 2009 list of antibacterial compounds in phase 2 or later development, but unfortunately none addresses the entire spectrum of clinically relevant GNB resistance. Our survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive. IDSA stresses our conviction that the antibiotic pipeline problem can be solved by the collaboration of global leaders to develop creative incentives that will stimulate new antibacterial research and development. Our aim is the creation of a sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 as called for in IDSA's “10 × '20 Initiative.”Keywords
This publication has 45 references indexed in Scilit:
- Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec TypesAntimicrobial Agents and Chemotherapy, 2012
- In vitro activity of BAL30072 against Burkholderia pseudomalleiInternational Journal of Antimicrobial Agents, 2011
- In Vivo Efficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2011
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2011
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial PneumoniaClinical Infectious Diseases, 2010
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-ChallengeNew England Journal of Medicine, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009